May 31

Hugo Lloris admits Spurs are ‘missing something’ as skipper doubts title hopes

first_imgHUGO LLORIS says Tottenham’s title bid is “missing something” – and he does not mean points.The North Londoners are ninth in the table, already seven points behind early leaders Liverpool and five behind Manchester City in second, after a sticky start to the season.2 Keeper Hugo Lloris says Spurs might not know until later in the season what has been missing from their performancesMauricio Pochettino’s men have won just one of their opening four matches and drawn two.Keeper and captain Lloris said: “Liverpool and Man City have the experience and they are really competitive.”I think, at the moment, there’s something missing from us.“We will see later in the season because things turn very quickly in football.”The most important thing is we focus on ourselves, to get points, to get consistency in the league. And we will see where we are in the table in April, in March.WE EXPECTED BETTER“That is the moment when you can win or lose European places or trophies. At the moment, we don’t want to lose focus with that type of question.”Spurs kicked off the campaign with a 3-1 home win over newly-promoted Aston Villa.But after a creditable 2-2 draw at reigning champs City they suffered a shock 1-0 defeat at home to struggling Newcastle.Tottenham then drew 2-2 at Arsenal in Sunday’s North London derby in their final match before the international break.Lloris, speaking ahead of France’s Euro 2020 qualifier against Albania on Saturday, admitted: “Unfortunately at Tottenham we didn’t have the start we expected.More on SpursHARRY ALL FOUR ITKane admits Spurs must win EIGHT games to rise into Champions League spotGossipALL GONE PETE TONGVertonghen wanted by host of Italian clubs as long Spurs spell nears endBELOW PARRSpurs suffer blow with Parrott to miss Prem restart after appendix operationPicturedSHIRT STORMNew Spurs 2020/21 home top leaked but angry fans slam silver design as ‘awful”STEP BY STEP’Jose fears for players’ welfare during restart as stars begin ‘pre-season’KAN’T HAVE THATVictor Osimhen keen on Spurs move but only if they sell Kane this summerLADBROKES 1-2-FREE Simply predict Liverpool, Rangers vs Celtic and Arsenal vs Spurs scores this weekend and win £1002″Even though we got good results against City and Arsenal away from home, we should have done better against Newcastle.”We all know the importance of home games and when I talk about consistency, we have to capable of winning that type of game.There’s now already a gap between them – Liverpool and Man City – and us.”Tottenham release throwback sky blue third kitlast_img read more

May 26

Vanuatu favourites after exciting win over PNG

first_imgThey made it 4 wins from 4 games as they overcame a rejuvenated PNG side by just 7 runs.PNG’s bowlers turned up after a below par performance on Tuesday to restrict Vanuatu to just 115 off their 20 overs after Vanuatu won the toss and elected to bat. Kabua Vagi Morea was tight with the ball taking 2/18 from his 4 overs and PNG were back to their best in the field with 2 run outs and some excellent catches.However, Vanuatu were determined to make it back to back wins and Patrick Matautaava responded with the wicket of PNG captain Chris Amini in the first over. Riley Hekure (41) and Dogodo Bau (23) steadied things to take it 2/58 and PNG looked to be well on track to victory.Vanuatu’s bowlers had other ideas and the introduction of Jelany Chilia (3/18) quickly turned the momentum as PNG lost 7/22 to be left 7 runs short at the end of the 20 overs.In the morning matches PNG and Vanuatu both recorded comfortable wins against Tonga and New Caledonia respectively while Tonga had their second successive win over an enthusiastic New Caledonia in the afternoon.Today is a rest day for cricket with matches resuming tomorrow at Amini Park.Round 3Vanuatu 7/285 (20) Nalin Nipiko 105, Ronald Tari 69, Simpson Obed 32, Joseph Nigote 2/57 defeated New Caledonia 9/51 (14.2) Emmanuel Katrawi 15*, Simpson Obed 2/7 , Shem Sala 2/7 by 234 runsPNG 9/190 (20) Jason Kila 74, Riley Hekure 47, Sione Manumuna 3/26, Timote Latu 2/37 defeated New Caledonia 10/76 (20) Aloisio Pau’u 22, Maamaloa Kuluka 21, Jason Kila 3/7, Alei Nao 2/15 by 114 runsRound 4Tonga 3/222 (20) Nicolasi Moala 86, Aloisio Pau’u 60, Nicholls Adjouhgniope 2/57 defeated New Caledonia 10/162 (19.3) Jonathan Lapacas 57*, David Magulu 21, Asiake Haukinima 3/9, Paula Palu 3/135 by 60 runsVanuatu 9/115 (20) Jonathon Dunn 41,  Andrew Mansale 32, Simpson Obed 32,  Kabua Vagi Morea 2/18, Hiri Hiri 2/20 defeated PNG 9/108 (20) Riley Hekure 41, Dogodo Bau 23, Jelany Chillia 3/18, Simpson Obed 2/13 by 7 runsPacific Games Points Table:last_img read more

August 19

National Museum presents theatrical excerpts by Ana Istarú

first_imgCosta Rica boasts a good number ofgroundbreaking Ticas, each of whom has shaped the country in myriad ways. Ana Istarú has taken her place among them as the quintessential “Renaissance woman.” In a career spanning three decades, the San José native has become an accomplished poet, playwright, and actress – and she can even deliver a good zinger.On March 11, the National Theater will present short theatrical works by Istarú, partly to celebrate her astonishing oeuvre, and partly to make you laugh. “Theater and Humor with Ana Istarú” is a series of excerpts from her works “Baby Boom en Paraíso” (“Baby Boom in Paradise”) and “Hombres de Escebeche” (“Men in a Pickle”).Istarú is acclaimed for her unflinching interest in difficult topics. In her recent one-woman show, “Virus,” she took on AIDS, cancer, and family secrets, creating a dozen distinct characters. Istarú is known for verse that explores female eroticism, and she co-wrote the screenplay for “Caribe,” an intensely political film about Caribbean farmers and the developers who seek to exploit them.The performance is designed to honor International Women’s Day, and although each excerpt covers the gamut of situations and themes, Istarú complements her comic writing with serious issues, often about gender relationships – sexuality, family, and motherhood.If you have a strong grasp of Spanish or want to improve your skills, Istarú’s work is a great opportunity, as she masterfully mimics different Costa Rican dialects. “Theater and Humor” is also the perfect sampler of local writing, from both an accomplished playwright and an extraordinary mujer.“Teatro y Humor con Ana Istarú” takes place March 11 at the National Museum, downtown San José. 10 a.m. Free. Info: RedCultura. Facebook Comments Related posts:Christmas-themed theater warms hearts this month ‘Shark Smile’ illuminates stage and sea ‘Blood Wedding’: García Lorca tragedy opens at Teatro Espressivo 12 days, 13 plays at National Theater Eventlast_img read more

July 20

EXCLUSIVE Controversial experiments that could make bird flu more risky poised to

first_img EXCLUSIVE: Controversial experiments that could make bird flu more risky poised to resume Yoshihiro Kawaoka (left) and Ron Fouchier (right) in 2012, after their work with H5N1 bird flu virus sparked a global controversy over research that can potentially make pathogens more dangerous to humans. By Jocelyn KaiserFeb. 8, 2019 , 8:45 PM Click to view the privacy policy. Required fields are indicated by an asterisk (*) A worker at a Centers for Disease Control and Prevention laboratory harvests avian flu viruses for sharing with other laboratories in 2013. Controversial lab studies that modify bird flu viruses in ways that could make them more risky to humans will soon resume after being on hold for more than 4 years. ScienceInsider has learned that last year, a U.S. government review panel quietly approved experiments proposed by two labs that were previously considered so dangerous that federal officials had imposed an unusual top-down moratorium on such research.One of the projects has already received funding from the National Institutes of Health’s (NIH’s) National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, and will start in a few weeks; the other is awaiting funding.The outcome may not satisfy scientists who believe certain studies that aim to make pathogens more potent or more likely to spread in mammals are so risky they should be limited or even banned. Some are upset because the government’s review will not be made public. “After a deliberative process that cost $1 million for [a consultant’s] external study and consumed countless weeks and months of time for many scientists, we are now being asked to trust a completely opaque process where the outcome is to permit the continuation of dangerous experiments,“ says Harvard University epidemiologist Marc Lipsitch.  Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Martin Enserink/Science James Gathany/CDC Sign up for our daily newsletter Get more great content like this delivered right to you! Country One of the investigators leading the studies, however, says he’s happy he can resume his experiments. “We are glad the United States government weighed the risks and benefits … and developed new oversight mechanisms. We know that it does carry risks. We also believe it is important work to protect human health,” says Yoshihiro Kawaoka of the University of Wisconsin in Madison and the University of Tokyo. The other group that got the green light is led by Ron Fouchier at Erasmus University Medical Center in Rotterdam, the Netherlands.In 2011, Fouchier and Kawaoka alarmed the world by revealing they had separately modified the deadly avian H5N1 influenza virus so that it spread between ferrets. Advocates of such gain of function (GOF) studies say they can help public health experts better understand how viruses might spread and plan for pandemics. But by enabling the bird virus to more easily spread among mammals, the experiments also raised fears that the pathogen could jump to humans. And critics of the work worried that such a souped-up virus could spark a pandemic if it escaped from a lab or was intentionally released by a bioterrorist. After extensive discussion about whether the two studies should even be published (they ultimately were) and a voluntary moratorium by the two labs, the experiments resumed in 2013 under new U.S. oversight rules. Email But concerns reignited after more papers and a series of accidents at federal biocontainment labs. In October 2014, U.S. officials announced an unprecedented “pause” on funding for 18 GOF studies involving influenza or the Middle East respiratory syndrome or severe acute respiratory syndrome viruses. (About half were later allowed to continue because the work didn’t fit the definition or was deemed essential to public health.)There followed two National Academy of Sciences workshops, recommendations from a federal advisory board, and a new U.S. policy for evaluating proposed studies involving “enhanced potential pandemic pathogens” (known as ePPPs). In December 2017, NIH lifted the funding pause and invited new GOF proposals that would be reviewed by a committee with wide-ranging expertise drawn from the Department of Health and Human Services (HHS) in Washington, D.C., and other federal agencies.Now, the HHS committee has approved the same type of work in the Kawaoka and Fouchier labs that set off the furor 8 years ago. Last summer, the committee reviewed the projects and made recommendations about risk-benefit analyses, safety measures to avoid exposures, and communications plans, an HHS spokesperson says.After the investigators revised their plans, the HHS committee recommended that they proceed. Kawaoka learned from NIH on 10 January that his grant has been funded. Fouchier expects the agency may hold off on making a funding decision until after a routine U.S. inspection of his lab in March.Kawaoka’s grant is the same one on H5N1 that was paused in 2014. It includes identifying mutations in H5N1 that allow it to be transmitted by respiratory droplets in ferrets. He shared a list of reporting requirements that appear to reflect the new HHS review criteria. For example, he must immediately notify NIAID if he identifies an H5N1 strain that is both able to spread via respiratory droplets in ferrets and is highly pathogenic, or if he develops an EPPP that is resistant to antiviral drugs. Under the HHS framework, his grant now specifies reporting timelines and who he must notify at the NIAID and his university.Fouchier’s proposed projects are part of a contract led by virologists at the Icahn School of Medicine at Mount Sinai in New York City (most of Project 5, Aim 3.1, and Project 6 in this letter). They include identifying molecular changes that make flu viruses more virulent and mutations that emerge when H5N1 is passaged through ferrets. The HHS panel did not ask that any proposed experiments be removed or modified. Suggestions included clarifying how his team will monitor workers for possible exposures and justifying the strains they plan to work with, which include H7N9 viruses, Fouchier says. HHS cannot make the panel’s reviews public because they contain proprietary and grant competition information, says the spokesperson. But critics say that isn’t acceptable. “Details regarding the decision to approve and fund this work should be made transparent,” says Thomas Inglesby, director of Center for Health Security of the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. The lack of openness “is disturbing. And indefensible,” says microbiologist Richard Ebright of Rutgers University in Piscataway, New Jersey. The critics say the HHS panel should at least publicly explain why it thought the same questions could not be answered using safer alternative methods.One researcher who has sympathized with both sides in the debate finds the safety conditions imposed on Kawaoka reassuring. “That list… makes a lot of sense,” says virologist Michael Imperiale of the University of Michigan in Ann Arbor. “At this point I’m willing to trust the system.”Click here and here to read more of our reporting on the H5N1 controversy.*Clarification, 9 February, 10:30 a.m.: This story has been updated to clarify that one goal of the controversial experiments is to make the H5N1 virus transmissible in mammals (often ferrets), not humans.*Update, 11 February, 2:46 p.m.: This story has been updated with reaction from a number of scientists, and a clarification of the studies proposed by Fouchier.last_img read more